ALBO - Albireo Pharma: View Ahead Of Phase 3 Data In Progressive Familial Intrahepatic Cholestasis In Mid-2020
Albireo Pharma (ALBO) was spun out from AstraZeneca (AZN) and is based in Boston, MA. The company's key flagship molecule is Odevixibat, an inhibitor of ileal bile acid transporter (IBAT), which prevents the reabsorption of bile acids from the ileum back to the liver through the enterohepatic circulation, and it is being developed for various orphan cholestatic liver diseases.
The bull case
Odevixibat has shown impressive Phase 2 data in Progressive Familial Intrahepatic Cholestasis, or PFIC. PFIC is a genetic childhood orphan cholestatic liver disease that is characterized by impaired bile